HF
OVID icon

HRT Financial’s Ovid Therapeutics OVID Stock Holding History

HRT Financial’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-123,316
Closed -$40K – 3449
2025
Q2 		$40K Buy
123,316
+97,724
+382% +$29.4K ﹤0.01% 2336
2025
Q1 		$7K Buy
+25,592
New +$15.7K ﹤0.01% 2385
2021
Q4 		– Sell
-114,493
Closed -$384K – 3839
2021
Q3 		$384K Sell
114,493
-17,022
-13% -$62.1K ﹤0.01% 2239
2021
Q2 		$514K Buy
+131,515
New +$519K ﹤0.01% 1744

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

HRT Financial's OVID Position: Q3 2025 in Review

HRT Financial sold out of Ovid Therapeutics (OVID) in Q3 2025, closing a stake of 123,316 shares — an estimated $40K sold.

HRT Financial first reported a position in OVID in Q2 2021 and held it in 4 quarters. The position peaked at $514K in Q2 2021. 81 funds tracked by Wall St. Rank hold OVID as of Q3 2025.

  • HRT Financial reported no remaining Ovid Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 123,316 Ovid Therapeutics shares in Q3 2025, an estimated $40K.
  • HRT Financial first reported a position in Ovid Therapeutics in Q2 2021 and held it in 4 quarters.
  • HRT Financial's Ovid Therapeutics position peaked at $514K in Q2 2021.
  • 81 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.